Evaluating the Impact of TrialTalk™ to Foster Equitable Cancer Care Delivery and Clinical Trial Participation

Sponsor:

Alliance Foundation Trials LLC

Sponsor Study ID:

UW24152

CTO #:

104244

NCT Number:

NCT06985953

Phase:

N/A

Protocol Type:

Health Services Research

Age Group:

Adults

Disease Sites:

Anus; Bladder; Bones and Joints; Brain and Nervous System; Breast; Cervix Uteri; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Ill-Defined Sites; Kaposi's Sarcoma; Kidney; Larynx; Leukemia, other; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, Skin; Multiple Myeloma; Mycosis Fungoides; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Hematopoietic; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites

Study Objectives:

Examine TrialTalk effectiveness by examining the changes in clinical tiral accrual from baseline by race and ethnicity among enrolled providers and at the institution level up to 12 months post- implementation. Examine the implementation outcomes of TrialTalk such as adoption, penetration, fidelity, feasibility, and acceptability with different stakeholder groups.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)